Although two phase III trials (LOGiC [27] and TyTAN [28]) for lapatinib, which is an EGFR and HER2 kinase inhibitor, failed to reach the primary endpoint, lapatinib did show modest single-agent activity in advanced/metastatic gastric cancer patients with a response rate of 9% [26]. Here, ERBB2 is linked to gastric cancer.